France Sets Precedent With Off-Label Avastin Move

True to its word, the French health ministry has announced that Roche's anticancer Avastin (bevacizumab) will be reimbursed for the off-label treatment of wet AMD as of Sept. 1, 2015. In doing so, the ministry is setting a precedent by encouraging the use of a drug for an unapproved indication for purely financial reasons.

True to its word, the French health ministry has announced that Roche's anticancer Avastin (bevacizumab) will be reimbursed for the off-label treatment of wet AMD as of Sept. 1, 2015. In doing so, the ministry is setting a precedent by encouraging the use of a drug for an unapproved indication for purely financial reasons.

This is a battle that the government has been fighting for some years, and one that it is clearly determined...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Archive

More from Scrip